New drug combo tested in fight against advanced lung cancer
NCT ID NCT05860296
Summary
This study tested a new oral drug, SLC-391, combined with the immunotherapy drug pembrolizumab in people with advanced non-small cell lung cancer (NSCLC). The first part aimed to find a safe dose for the combination. The second part aimed to see if the combination could help stop tumors from growing or spreading. The study was terminated early and enrolled 36 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Community Health Network
Indianapolis, Indiana, 46250, United States
-
Cross Cancer Institute
Edmonton, Alberta, Canada
-
Horizon Verdi Oncology
Lafayette, Indiana, 47905, United States
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Juravinski Cancer Centre
Hamilton, Ontario, Canada
-
Karmanos Cancer Center
Detroit, Michigan, 48201, United States
-
London Regional Cancer Centre
London, Ontario, Canada
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Conditions
Explore the condition pages connected to this study.